Cerebral palsy (CP) is highly prevalent, with an international prevalence of 1-5%. Spasticity accounts for a large proportion of cerebral palsy (about 70-75%). Spastic cerebral palsy is characterized by increased muscle tone, which leads to motor dysfunction. Therefore, lowering muscle tone and promoting motor development is the focus of treatment. Treatment of spastic cerebral palsy is a difficult clinical problem. Muscle spasms can lead to tendon contractures, joint deformities, and can also affect bone development, and in severe cases, joints and bones are deformed, resulting in abnormal postures, which seriously affects the motor function of the child. Treatment of spastic cerebral palsy: such as: nerve blockers (alcohol, phenol, etc.), tendon lengthening, and selective dorsal spinal nerve rhizotomy (SPR), baclobutrazolol pumps and other treatments, which are often accompanied by neuromuscular injuries, and can be associated with severe muscle weakness, easy to recur, and other side effects, and the effectiveness of the treatment is unsatisfactory. Local intramuscular injection of BTX-A can safely treat spastic cerebral palsy, effectively relieving muscle spasm, expanding joint mobility, improving gait, mobility and locomotion, as well as preventing tendon contractures and osteoarthritic deformities and malformations. By injecting botulinum toxin, muscle spasm can be relieved quickly and muscle tension can be reduced. Botox injections are skill and art. Botox injection is very demanding. Selected indications and target muscles, the appropriate application, in order to be able to achieve immediate results. However, Botox injection is not a cure-all, but only provides the opportunity for rehabilitation treatment within a time period. Specialized, formal and effective comprehensive rehabilitation should be carried out after the injection, otherwise the expected results will not be achieved. The optimal age is 2-6 years old. Indications 1, to reduce spasticity of target muscles (mainly choose the target muscles that are difficult or ineffective to be treated by manipulation); 2, spasticity with the purpose of short-term improvement of function, improvement of care, prolongation of the operation, and can be treated with repeated injections if necessary. 3, Prevention of (hip) joint subluxation, dislocation; 4, As limb (orthopedic) preoperative preparation or postoperative management; 5, Improvement of salivation; 6, Relief of pain, postoperative analgesia. Main adverse reactions 1, pain, muscle weakness, fatigue; 2, flu-like symptoms, fever, rash; 3, neighboring muscle weakness, such as urinary incontinence, constipation, pneumonia, etc.; 4, transient unsteadiness of standing or unsteady gait. Contraindications 1, hypotonic cerebral palsy; 2, children with neuromuscular junction diseases (e.g. myasthenia gravis); 3, those who need to apply drugs interfering with neuromuscular transmission at the same time (e.g. aminoglycoside antibiotics); 4, cerebral palsy children with fixed deformities (e.g. shortening of tendons, contracture of joints, etc.); 5, fever, acute infectious diseases; 6, heart disease, liver dysfunction, severe pneumonia; 7, blood system diseases, such as fever, skin rash; 7, blood system diseases, such as urinary incontinence, constipation, pneumonia; 8, a transient standing or gait stabilization. Pneumonia; 7, Hematologic diseases, coagulopathies or those who receive anticoagulant therapy at the same time; 8, Severe allergies, rash period; 9, Previously used partial neurectomy, nerve blockers to treat spasticity.